NOTTINGHAM, England--(BUSINESS WIRE)--Locate Bio, a pioneering orthobiologics company, today announces the successful completion of an oversubscribed £9.2 million funding round from both new investors and existing investors, Mercia Ventures and BGF. The proceeds will fund a clinical study of LDGraft, a bone graft substitute for spinal fusion..

英国诺丁汉--（商业新闻短讯）--开创性的orthobiologics公司Locate Bio今天宣布，新投资者和现有投资者Mercia Ventures和BGF成功完成了一轮920万英镑的超额认购融资。收益将用于LDGraft的临床研究，LDGraft是脊柱融合的骨移植替代品。。

This funding and the clinical trial known as RESTORE (A Randomized Study of LDGraft in Single Level Anterior Lumbar Interbody Fusion) marks a significant milestone in the company's mission to relieve suffering and restore the quality of life for millions of patients suffering from debilitating orthopaedic conditions worldwide..

这笔资金和名为RESTORE的临床试验（一项单节段腰椎前路椎体间融合术中LD移植物的随机研究）标志着该公司缓解全球数百万骨科疾病患者痛苦和恢复生活质量的使命中的一个重要里程碑。。

Locate Bio combines decades of research in advanced drug delivery systems and utilises a proprietary protein encapsulation method to deliver a powerful therapeutic protein called rhBMP-2. This is combined with an osteoconductive scaffold in LDGraft, which received a US Food and Drug Administration (FDA) breakthrough device designation in 2023..

Locate Bio结合了数十年来对先进药物输送系统的研究，并利用专有的蛋白质包封方法来输送一种强大的治疗性蛋白质，称为rhBMP-2。这与LDGraft中的骨传导支架相结合，LDGraft于2023年获得美国食品和药物管理局（FDA）突破性的设备指定。。

CEO John von Benecke said, “This oversubscribed funding round underscores the significant investor confidence in the company's vision and the potential of LDGraft to become the most relied-on bone graft substitute globally.”

首席执行官约翰·冯·贝内克（JohnVonBenecke）表示：“这轮超额认购资金突显了投资者对公司愿景的巨大信心，以及LDGraft成为全球最依赖骨移植替代品的潜力。”

'With the rapidly ageing global population, there is an urgent need for products that address chronic, progressive, and debilitating back pain,' added von Benecke. “With a design inspired by nature for a more biomimetic approach to the release of rhBMP-2, we are incredibly excited about the potential of LDGraft.

冯·贝内克补充道：“随着全球人口的迅速老龄化，迫切需要解决慢性、进行性和衰弱性背痛的产品。”。“设计灵感来自大自然，采用更仿生的方法释放rhBMP-2，我们对LDGraft的潜力感到无比兴奋。

The RESTORE clinical trial is an important step towards realising that ambition.”.

RESTORE临床试验是实现这一雄心壮志的重要一步。”。

Jonathan Earl, investor at BGF, said: “Locate Bio has demonstrated significant progress in its drive towards developing innovative solutions that address a wide range of musculoskeletal needs. Their approach represents a significant breakthrough in this field and we look forward to providing continued support for the business as it moves through clinical trials and towards regulatory approval.”.

BGF投资者乔纳森·厄尔（JonathanEarl）表示：“Locate Bio在开发创新解决方案以满足广泛的肌肉骨骼需求方面取得了重大进展。他们的方法代表了该领域的重大突破，我们期待着在该业务通过临床试验和监管批准时继续为其提供支持。”。

Alex Gwyther, investor at Mercia Ventures, said: “We have long believed in Locate Bio’s mission to develop next generation orthobiologics that can transform patients’ lives. We are pleased to see both the progress in the technology and the world-class team that the company has brought together.”

Mercia Ventures的投资者Alex Gwyther表示：“我们一直相信Locate Bio的使命是开发可以改变患者生活的下一代正畸生物制剂。我们很高兴看到该技术的进步和该公司汇集的世界级团队。”

About Locate Bio

关于定位Bio

Locate Bio is a UK-based, pioneering orthobiologics company committed to advancing medical innovation and transforming patient care.

Locate Bio是一家总部位于英国的开创性orthobiologics公司，致力于推进医疗创新和改变患者护理。

Our vision is to build a world-leading orthobiologics company with products that dominate their respective market segments and where our people grow to their full potential.

我们的愿景是建立一家世界领先的orthobiologics公司，其产品主导各自的细分市场，并使我们的员工充分发挥潜力。

Locate Bio is a spin-out from the University of Nottingham. The Company is backed by Mercia Ventures and BGF.

Locate Bio是诺丁汉大学的衍生产品。该公司由Mercia Ventures和BGF支持。

For more information about Locate Bio and its ground-breaking work, please visit www.locatebio.com

有关Locate Bio及其开创性工作的更多信息，请访问www.locatebio.com

About Mercia Ventures

关于Mercia Ventures

Mercia Ventures is a proactive venture capital investor focused on being the first-choice partner for growth. Mercia Ventures makes equity investments of up to £10 million across all sectors, with specialisms in Software, Consumer, Healthcare and Deep Tech.

Mercia Ventures是一家积极主动的风险投资公司，专注于成为增长的首选合作伙伴。Mercia Ventures在所有行业进行高达1000万英镑的股权投资，专注于软件、消费者、医疗保健和深度技术。

Mercia Ventures is part of Mercia Asset Management PLC and sits alongside its wider private equity, debt and proprietary balance sheet capital operations. The Group has 11 offices in the UK and Mercia Ventures’ national footprint and 48 strong investment team draws on their experiences as founders, PhD scientists, software engineers, corporate financiers and management consultants to help its partner companies successfully achieve their ambitions..

Mercia Ventures是Mercia Asset Management PLC的一部分，与其更广泛的私人股本、债务和专有资产负债表资本运营并列。该集团在英国拥有11个办事处，Mercia Ventures在全国拥有分支机构，48支强大的投资团队凭借其作为创始人、博士科学家、软件工程师、企业金融家和管理顾问的经验，帮助其合作伙伴公司成功实现其雄心。。

www.mercia.co.uk

www.mercia.co.uk

About BGF

关于BGF

BGF was set up in 2011 and has invested over £3.9 billion in more than 560 companies, making it the most active growth capital investor in the UK and Ireland.

BGF成立于2011年，已向560多家公司投资39亿英镑，是英国和爱尔兰最活跃的增长资本投资者。

BGF has to date invested £200 million in the field of life sciences, supporting companies across the fields of diagnostics, medtech and digital health, as well as services, software and tools supporting therapeutic development.

迄今为止，BGF已在生命科学领域投资2亿英镑，支持诊断、医学技术和数字健康领域的公司，以及支持治疗开发的服务、软件和工具。

BGF is a minority, non-controlling equity partner with a patient outlook on investments, based on shared long-term goals with the management teams it backs. BGF invests in growing businesses in the UK and Ireland through its network of 15 offices.

BGF是一家少数、非控股的股权合作伙伴，基于与其支持的管理团队共同的长期目标，对投资有耐心的展望。BGF通过其15个办事处的网络投资于英国和爱尔兰不断增长的业务。

www.bgf.co.uk

www.bgf.co.uk